Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P., both entities with a ten percent ownership stake in ARS Pharmaceuticals (NASDAQ:SPRY), sold a combined total of 740,149 shares of Class A Common Stock on June 27, 2025, for approximately $13.7 million. The transaction comes as ARS Pharmaceuticals, currently valued at $1.58 billion, trades near its 52-week high of $18.90. According to InvestingPro data, the stock has delivered an impressive 99.9% return over the past year. The sales occurred at a weighted average price of $18.46, with individual transactions ranging from $18.20 to $18.89.
According to a Form 4 filing with the Securities and Exchange Commission, Deerfield Private Design Fund III, L.P. disposed of 370,075 shares. Following this transaction, Deerfield Private Design Fund III, L.P. still owns 4,887,254 shares. Deerfield Private Design Fund IV, L.P. disposed of 370,074 shares. Following this transaction, Deerfield Private Design Fund IV, L.P. still owns 4,887,254 shares.
Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P.
In other recent news, ARS Pharmaceuticals reported its first-quarter 2025 earnings, surpassing revenue forecasts with a total of $8 million. This performance was primarily driven by the successful launch of its needle-free epinephrine treatment, NEFI. Despite the revenue beat, the company reported a net loss of $33.9 million, or $0.35 per share. Additionally, Raymond (NSE:RYMD) James maintained its Strong Buy rating on ARS Pharmaceuticals, with a price target of $32.00, after adjusting its second-quarter net sales estimate for NEFI to $12.8 million. This adjustment was based on discussions with management that revealed high script capture rates. The firm noted that investors are more focused on sales during the back-to-school peak in the third and fourth quarters. ARS Pharmaceuticals is also progressing with regulatory reviews in international markets, with launches expected from mid-2025 to early 2026. The company anticipates a sales inflection in the third quarter of 2025, with peak sales expected in August and September.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.